Lotte Biologics plans to start commercial production next year and targets 1 trillion won in annual sales by 2030
Lotte Group on Wednesday held a completion ceremony for its first biopharmaceutical manufacturing plant in Songdo, Incheon, as the retail conglomerate seeks to diversify its business portfolio beyond its traditional retail, food and chemical operations.
"The bio business is Lotte Group's future growth engine and an industry that will lead Korea's next generation," Shin Dong-bin, chairman of Lotte Group, said during the ceremony.
"I hope Plant 1 of the Songdo Bio Campus will become an important turning point that goes beyond Lotte Group's growth and raises the competitiveness of Korea's bio industry to the next level."
The completion of the contract development and manufacturing organization, or CDMO, site came less than three years after Lotte Biologics broke ground in March 2024.
The Songdo facility represents the second pillar of Lotte Biologics' expansion strategy, following its $160 million acquisition of a biopharmaceutical manufacturing facility from Bristol Myers Squibb in Syracuse, New York, in 2022.
"(This) is meaningful not only because it marks the completion of a new production facility, but because it lays the groundwork for Lotte Biologics to contribute to strengthening the large-scale manufacturing capabilities of Korea's bio industry," said Shin Yoo-yeol, co-CEO of Lotte Biologics and the eldest son of Chairman Shin.
"Under our new vision, 'The New Benchmark for Next Generation CDMOs,' we will be a CDMO partner that walks alongside our customers over the long term, built on the quality, technology and trust they can truly feel."
Lotte Biologics announced on the previous day that it had secured its first major commercial manufacturing contract for the Songdo Bio Campus. It did not disclose the client or contract value.
Built on a site spanning approximately 100,000 square meters, Lotte Biologics' first Songdo plant houses eight stainless-steel bioreactors, each with a capacity of 15,000 liters, alongside smaller-scale cultivation facilities, including 3,000-liter bioreactors.
According to Lotte Biologics, the combination is designed to accommodate customers with varying production requirements, from smaller batches to large-scale commercial manufacturing.
"Plant 1 of the Songdo Bio Campus achieved (good manufacturing practice) six months ahead of the original plan," James Park, co-CEO of Lotte Biologics, said.
"This is the result of the efforts and dedication of all our employees and it will serve as a solid foundation for growth as we take another step forward in the global market."
As Lotte Biologics plans to begin commercial operation at the plant next year, the company laid out a road map to achieve 1 trillion won ($751 million) in annual sales by 2030, with plans to expand its Songdo operations through the construction of second and third plants.
According to the company, Plant 1 alone could generate about 700 billion won in sales for a year if run at full capacity.
Lotte Biologics added that it will push to go public as part of efforts to formalize its corporate value and support future expansion amid the growing biopharmaceutical market worldwide.
"We expect the trend of outsourcing drug manufacturing to expand and supply chain realignment driven by geopolitical uncertainty to accelerate," Chun Ji-won, chief growth officer at Lotte Biologics, said.
"Based on our dual-site strategy linking Songdo and Syracuse, Lotte Biologics will transfer the production operation know-how of the Syracuse plant to Songdo and take advantage of the tariff benefits of local production in the US, responding flexibly to the diverse needs of global clients."
hwkan@heraldcorp.com
